Organon & Co.

Organon & Co. is a healthcare company that develops and supplies pharmaceutical treatments centered on women’s health and general medicine. Its business is organized into women’s health, biosimilars, and established brands. The women’s health segment focuses on prescription contraception and fertility treatments, including implants, vaginal rings, and follicle-stimulating injections. Its biosimilar offerings treat immunology and oncology conditions, while the established brands portfolio covers cardiovascular, respiratory, dermatology, bone health, and non-opioid pain medications. Organon distributes its products to drug wholesalers, retailers, hospitals, government agencies, and managed care institutions such as pharmacy benefit managers and health maintenance organizations.

The company distributes medications across more than 140 countries and territories, with its women’s health offerings available in over 90 international markets. It operates six manufacturing facilities situated in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom. Organon employs over 10,000 people globally, with around 1,500 workers located in the United States and Puerto Rico. The provided text does not state the company's headquarters.

Summary of the business section of Organon's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had over 10,000 employees worldwide with approximately 1,500 (15%) employees in the United States, including Puerto Rico.”